In short
A new clinical trial is investigating the use of Polyinosinic:polycytidylic Acid, also known as BO-112, for treating basal cell carcinoma (BCC). This Phase 2b study aims to evaluate the safety, tolerability, and effectiveness of BO-112 when injected directly into BCC lesions. The trial focuses on patients with resectable primary low and high-risk basal cell carcinoma, offering a potential new approach to treating this common skin cancer.
At a glance
- Drug Name
- Polyinosinic:polycytidylic Acid (BO-112)
- Trial Phase
- Phase 2b
- Condition Studied
- Resectable primary low and high-risk basal cell carcinoma
- Administration Method
- Intra-lesional injection
- Primary Objective
- Evaluate efficacy of BO-112 in resectable primary low or high-risk BCC
- Secondary Objectives
- Evaluate safety, tolerability, and recurrence rate
- Key Inclusion Criteria
- Age ≥18, primary resectable BCC, adequate organ function
- Key Exclusion Criteria
- Pregnancy, immunocompromised status, recent cancer therapies
- Primary Endpoint
- Complete visual and pathological response at surgery
- Maximum Daily Dose
- 2 mg
- Maximum Total Dose
- 6 mg
- Treatment Duration
- Up to 3 weeks
What is BO-112?
BO-112 is a medication being studied for the treatment of basal cell carcinoma, a type of skin cancer. Its active ingredient is polyinosinic:polycytidylic acid, also known as Poly I:C. This drug is administered as a solution for injection directly into the tumor, a method called intratumoral injection.
How BO-112 Works
BO-112 is classified as an immunotherapy drug. While the exact mechanism isn't fully explained in the provided information, immunotherapy drugs generally work by stimulating the body's immune system to fight cancer cells. The intratumoral injection method allows the medication to be delivered directly to the cancer site.
Target Condition: Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common type of skin cancer. It typically develops on areas of skin exposed to the sun, such as the face and neck. The clinical trial is studying BO-112 for both low-risk and high-risk BCC.
Clinical Trial Details
The clinical trial for BO-112 is called SPOTLIGHT 204. It's a Phase 2b trial, which means it's testing the drug's effectiveness and safety in a larger group of people after initial safety studies have been completed. Key details include:
- It's an open-label trial, meaning both patients and doctors know which treatment is being given.
- The trial is non-randomized, so all eligible participants receive BO-112.
- The main goal is to evaluate how well BO-112 works when injected into BCC tumors.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria. Some key requirements include:
- Being 18 years or older
- Having primary resectable (removable by surgery) low or high-risk basal cell carcinoma
- Having adequate organ function
- Not being pregnant or breastfeeding
- Not having received certain other treatments recently
- Not having certain other medical conditions that might interfere with the study
It's important to note that these are just some of the criteria. A healthcare provider can provide more detailed information about eligibility.
Potential Benefits
The potential benefits of BO-112 are still being studied, but the trial aims to evaluate:
- How effective BO-112 is in treating BCC
- Whether it can lead to complete removal of the cancer, as assessed visually and through pathology (examination of tissue samples)
- How it affects the recurrence rate of BCC after treatment
Safety Considerations
As with any medical treatment, safety is a crucial consideration. The trial will closely monitor:
- Side effects (adverse events) of BO-112
- Any serious adverse events
- Any side effects that lead to stopping treatment or are life-threatening
It's important to remember that BO-112 is still an experimental treatment. While it shows promise, its full effects and potential risks are not yet fully known. Patients considering participating in the trial should discuss all potential risks and benefits with their healthcare provider.